NOVEL STRATEGY FOR IMPROVING BIOAVAILABILITY OF OCULAR DRUG DELIVERY USING COLLOIDAL NANOSUSPENSION

Nowadays, a very large proportion of new drug candidates arising from drug discovery programs are water-insoluble and, for that reason, poorly bioavailable. The trouble is even more complex for drugs that belong to the BCS Class II category. To overcome these problems, nanotechnology is used to enhance the solubility as well as bioavailability of poorly soluble drugs. In the ocular drug transport system, ocular infections are dealt with by various topical drug applications in the form of solutions, suspensions, and ointment. These conventional dosage forms go through from the problems of poor ocular bioavailability due to minimal ocular residence time because of various anatomical and pathophysiological barriers prevailing in the eye. Nanotechnology refers to the particle size range of 1–1000 nm. Nanosuspensions are a part of Nanotechnology. Nanosuspensions are defined as the submicron colloidal dispersions of pharmaceutically active ingredient particles in a liquid phase, the measurement under 1μm, without any matrix material, which is stabilized by surfactants and polymers. Major concerns with topical ocular delivery include poor drug absorption and low bioavailability. Thus nanosuspension is an efficient technology to enhance the bioavailability of the ocular drug delivery system. This review article ordinarily focuses on an overview of ocular obstacles to anterior section delivery, along with ways to overcome these barriers using nanocarrier systems. Nanosupension not solely solves the trouble of poor solubility and bioavailability however also alter the pharmacokinetics of the drug and thus improving protection and efficacy.